Bringing the Oncology Community Together

Dr. von Minckwitz on the Rationale of PENELOPE

Gunter von Minckwitz, MD, PhD
Published Online: Thursday, January 23, 2014
Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses the rationale behind the phase III PENELOPE trial.

It has been known for a while that patients who do not reach pathologic complete response (pCR) after neoadjuvant chemotherapy have a worse prognosis compared with those who do achieve pCR.

The NATAN study had investigated the use of a bisphosphonate in this setting, though improvement in event-free survival could not be achieved. This further proved the need for new treatment options.

Upon the announcement of progression-free survival benefit in a phase II study of palbociclib plus letrozole, von Minckwitz says oncologists believed the combination should be moved to an early disease setting. A conclusion was then reached to identify patients who have not achieved pCR to be candidates for a “post-neoadjuvant” study investigating palbociclib.

Related Articles
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
New ASCO Guideline Expands Recommendation for SLN Biopsy Use in Early Stage Breast Cancer
An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.